Send the following on WhatsApp
Continue to ChatTwo Novartis Phase III studies show twice as many Ph+ CML patients achieve deeper levels of response with Tasigna® compared to Glivec® https://zedie.org/2011/12/12/two-novartis-phase-iii-studies-show-twice-as-many-ph-cml-patients-achieve-deeper-levels-of-response-with-tasigna-compared-to-glivec/